- Max Healthcare’s net income for the first quarter of 2024 is 2.36 billion rupees, showing a 1.7% decrease compared to the same period last year.
- Revenue has risen to 15.4 billion rupees, which marks a substantial 20% increase year-over-year.
- Total costs have increased by 24% year-over-year, reaching 12.6 billion rupees.
- The company has entered into a lease agreement for a hospital with 250+ beds.
- Analyst recommendations include 13 buys, 3 holds, and 3 sells.
A look at Max Healthcare Institute Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Max Healthcare Institute Limited, a leading chain of hospitals in India, shows promising long-term potential based on its strong Smartkarma Smart Scores. The company excels in growth opportunities with a high score of 5, indicating a robust upward trajectory. Additionally, Max Healthcare demonstrates impressive resilience and momentum with scores of 4 in both categories, showcasing its ability to adapt to challenges and sustain positive performance. While the value and dividend scores are moderate at 2, the overall outlook for Max Healthcare Institute appears optimistic, underpinned by its diverse range of healthcare services catering to various medical needs.
Max Healthcare Institute Limited, with its focus on urology, oncology, orthopaedics, eye care, and other specialized services, continues to attract patients seeking quality healthcare solutions. The company’s emphasis on innovation and growth, coupled with its solid foundation in patient care, positions it well for long-term success in the healthcare industry. Investors may find Max Healthcare Institute appealing due to its strong growth prospects and steady performance in the face of challenges, making it a noteworthy player in India’s healthcare sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
